Contact us
Please enter your contact details and the Digital Pathology Solutions team will be in touch.
Frequently asked questions
Everything you need to know about our models, solutions, deployment, and getting in touch.
We build clinical-grade AI that reads whole-slide images the way a pathologist does — quantifying biomarkers, scoring stains, and surfacing the regions that matter. Our platform plugs into the reporting workflow your lab already uses, so adoption never means rebuilding your process from scratch.
Our clinical suites cover breast (HER2, Ki-67, ER, PR) and immuno-oncology (PD-L1, p53, CD4/CD8, TRBC1/CD3), with a shared architecture that scales to new indications. Because every suite runs on the same foundation model, accuracy and behaviour stay consistent across stains, scanners and sites.
Clinical solutions are built for diagnostic confidence and regulatory alignment, while research solutions prioritise flexibility — custom endpoints, batch analysis and dataset curation. Many teams start in research mode and graduate the same biomarker into a validated clinical workflow.
One model architecture, validated across stains and scanners, rather than a patchwork of narrow point-solutions. That means reproducible scoring, fewer edge-case failures, and results you can defend — particularly in the equivocal cases where automated tools usually struggle.
We deploy in the environment that fits your governance — cloud, on-premise, or hybrid — and integrate with your LIS/LIMS and scanner fleet. Roll-out is staged: validation first, then a supervised pilot, then routine use, so your team builds trust before anything touches a real report.
No. Results are delivered inside the reporting workflow your team already uses, as a decision-support layer rather than a replacement. Pathologists stay in control and sign out every case — the AI simply makes the quantitative work faster and more reproducible.
Patient data is encrypted in transit and at rest, processed within infrastructure that meets healthcare-grade security standards, and never used to train models without explicit agreement. Access is role-scoped and fully auditable, and on-premise deployment is available where data residency requires it.
Every model is validated against pathologist-annotated ground truth across multiple sites, stains and scanner types, with documented performance metrics. We also support local validation in your own lab before routine use, so you can confirm performance on your specific cohort.
Regulatory status depends on the specific suite and region. Some products are CE-marked for clinical use, while others are offered for research use only. Our team will walk you through exactly what is available — and in what mode — for your jurisdiction.
Yes. We support biomarker-driven drug development with reproducible, multi-site scoring that reduces inter-reader variability across trial centres. This gives sponsors consistent, auditable readouts that hold up across the full length of a study.
Send the form above with a short note on your indication and scanner setup, and our team will scope a pilot with you. A typical engagement starts with a scoped validation on your own slides, so you see real performance on your data before committing.
Depending on the team you select above, you'll speak with our clinical, research, or partnerships specialists — not a generic sales queue. Expect a substantive technical conversation, and we'll bring the right scientists into the room when it helps.
Still have questions?
We're happy to help.
Use the form above and the right specialist on our team will be in touch.